Uncategorized Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating Post Content
Uncategorized Craig-Hallum Reiterates a Buy Rating on Clover Health Investments (CLOV), Sets a $6 PT Post Content
Uncategorized H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 Post Content